论文部分内容阅读
调查肝细胞癌(hepatocellular carcinoma,HCC)患者体内细胞因子的变化情况,我们对40例HCC患者的IL-6,IL-2和可溶性白介素-2受体(sIL-2R)进行了检测,并与肝硬变患者进行了比较。 1 材料和方法 1.1 材料 1995-06/1998-06在我科住院的HCC患者40例,诊断依据临床表现、实验室检查和CT或核磁共振(MRI)等影象学资料,4例经手术后病理证实,符合《中国常见恶性肿瘤诊治规范》标准,男32例,女8例;平均年龄54岁。对照组肝炎肝硬变(LC)26例,男19例,女7例;平均年龄51岁。所有病例HBsAg阳性,其中19例重叠HCV感染,以66例健康献血员为正常对照组(normal control,NC),检测IL-6 20例、IL-2 16例,sIL-2R 30例,所有病例采血前无免疫制剂应用史,2wk内无细
To investigate the changes of cytokines in patients with hepatocellular carcinoma (HCC), we tested the levels of IL-6, IL-2 and soluble interleukin-2 receptor (sIL-2R) in 40 HCC patients. Patients with cirrhosis were compared. 1 Materials and methods 1.1 Materials 40 cases of HCC patients hospitalized in our department from 1995-06/1998-06 were diagnosed according to clinical manifestations, laboratory examinations, and CT or magnetic resonance imaging (MRI) and other imaging data. 4 cases were treated with surgery. Pathologically confirmed, in line with “Chinese common malignancy diagnosis and treatment norms” standard, 32 males and 8 females; average age 54 years. The control group had 26 cases of hepatitis cirrhosis (LC), 19 males and 7 females; the average age was 51 years. All cases were positive for HBsAg, 19 of them overlapped with HCV infection, and 66 healthy blood donors were normal controls (NC). There were 20 patients with IL-6, 16 patients with IL-2, and 30 patients with sIL-2R. There is no history of application of immunological preparations before blood collection, no fine in 2 weeks